文献速递精神分裂症与精神病性障碍

急性精神分裂症安慰剂对照抗精神病药试验六十年:系统综述、贝叶斯Meta分析与疗效预测因素Meta回归

Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
PubMed 文献 · Am J Psychiatry · 2017-05-25

该研究系统检索多个电子数据库,纳入167项双盲随机对照试验、28102例主要为慢性期的急性加重精神分裂症患者,采用贝叶斯Meta分析与Meta回归评估抗精神病药总体疗效及预测因素。结果显示总体疗效SMD为0.47(95%可信区间0.42,0.51),校正小试验效应与发表偏倚后降至0.38;抗精神病药组至少「最小」应答者占51%而安慰剂组为30%,「良好」应答者分别为23%与14%;仅工业赞助与安慰剂应答升高是效应量的显著调节因素,药物应答随时间保持稳定。

要点

  • 抗精神病药总体疗效SMD为0.47(95%可信区间0.42,0.51),校正后为0.38。
  • 至少「最小」应答者抗精神病药组51%、安慰剂组30%,「良好」应答者23%与14%。
  • 仅工业赞助与安慰剂应答升高显著调节效应量,药物应答未随时间下降。

核心结论

  • 抗精神病药治疗急性精神分裂症的应答率约为安慰剂的2倍,但仅少数患者达到良好应答。
  • 效应量下降与工业赞助及安慰剂应答升高有关,而非药物应答随时间减弱。

研究设计与样本

  • 系统综述与贝叶斯Meta分析,检索多个电子数据库。
  • 纳入167项双盲随机对照试验,共28102例主要为慢性期的急性加重精神分裂症患者。
  • 采用Meta回归分析疗效的潜在调节因素。

主要发现

  • 总体疗效标准化均数差(SMD)为0.47(95%可信区间0.42,0.51),校正小试验效应与发表偏倚后为0.38。
  • 至少「最小」应答者抗精神病药组51%、安慰剂组30%;「良好」应答者分别为23%与14%。
  • 阳性症状SMD为0.45,高于阴性症状SMD 0.35与抑郁症状SMD 0.27。
  • 生活质量SMD为0.35、功能SMD为0.34,短期即有改善。
  • 抗精神病药间副作用差异显著;分析的因素中16项试验特征随年代变化。

关键数值与推荐

  • 总体疗效SMD 0.47(95%可信区间0.42,0.51),校正后0.38。
  • 至少「最小」应答率51%对30%,「良好」应答率23%对14%。
  • 阳性症状SMD 0.45、阴性症状SMD 0.35、抑郁症状SMD 0.27。
  • 生活质量SMD 0.35、功能SMD 0.34。
  • 多变量Meta回归中仅工业赞助与安慰剂应答升高为效应量的显著调节因素。

临床怎么用

  • 临床应预期约半数患者达到至少最小应答,但良好应答者仅约四分之一。
  • 解释试验证据时需考虑工业赞助与安慰剂应答升高对效应量的影响。
  • 药物开发可考虑更小样本但更好筛选患者。

局限性

  • 纳入患者主要为慢性期,结论外推至首发患者需谨慎。
  • 小试验效应与发表偏倚使效应量估计可能偏高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Antipsychotic drug efficacy may have decreased over recent decades. The authors present a meta-analysis of all placebo-controlled trials in patients with acute exacerbations of schizophrenia, and they investigate which trial characteristics have changed over the years and which are moderators of drug-placebo efficacy differences. METHOD: The search included multiple electronic databases. The outcomes were overall efficacy (primary outcome); responder and dropout rates; positive, negative, and depressive symptoms; quality of life; functioning; and major side effects. Potential moderators of efficacy were analyzed by meta-regression. RESULTS: The analysis included 167 double-blind randomized controlled trials with 28,102 mainly chronic participants. The standardized mean difference (SMD) for overall efficacy was 0.47 (95% credible interval 0.42, 0.51), but accounting for small-trial effects and publication bias reduced the SMD to 0.38. At least a "minimal" response occurred in 51% of the antipsychotic group versus 30% in the placebo group, and 23% versus 14% had a "good" response. Positive symptoms (SMD 0.45) improved more than negative symptoms (SMD 0.35) and depression (SMD 0.27). Quality of life (SMD 0.35) and functioning (SMD 0.34) improved even in the short term. Antipsychotics differed substantially in side effects. Of the response predictors analyzed, 16 trial characteristics changed over the decades. However, in a multivariable meta-regression, only industry sponsorship and increasing placebo response were significant moderators of effect sizes. Drug response remained stable over time. CONCLUSIONS: Approximately twice as many patients improved with antipsychotics as with placebo, but only a minority experienced a good response. Effect sizes were reduced by industry sponsorship and increasing placebo response, not decreasing drug response. Drug development may benefit from smaller samples but better-selected patients.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Leucht S, Leucht C, Huhn M, et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017. PMID: 28541090. doi:10.1176/appi.ajp.2017.16121358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。